PROtein, Leucine and Vitamin D Supplementation In Patients With GYnecologic Cancer Receiving Platinum-based Chemotherapy

Inclusion Criteria:

• histologically confirmed diagnosis of gynecologic cancer (ovarian, uterine,cervical);

• indication for a first-line chemotherapy (adjuvant or curative) with aplatinum-based regimen to be used by investigator's choice within the framework ofgood clinical practice and in agreement with current Italian Association of MedicalOncology guidelines;

• Eastern Cooperative Oncology Group (ECOG) performance status ≤2;

• signed informed consent.

Exclusion Criteria:

• age <18 years

• ECOG performance status >2

• indication to or ongoing artificial nutrition support

• known kidney failure (previous glomerular filtration rate <30 ml/min);

• known liver failure (Child B or C)

• endocrine disorders associated with disorders of calcium metabolism (excludingosteoporosis)

• decompensated diabetes

• indications related to the study product: more than 10 µg (400 IU) of daily VitaminD intake from medical sources More than 500 mg of daily calcium intake from medicalsources; adherence to a high energy or high protein diet up or use of proteincontaining or amino acid containing nutritional supplements up to three monthsbefore starting the study.

• known allergy to milk, milk products or other components of the proposedinterventions

• inclusion in other nutritional intervention trials

• patients refusal